Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy

BACKGROUND: The clinical utility of plasma tumor mutational burden (pTMB) requires further validation. Herein, the pTMB and genetic alterations were investigated as predictive biomarkers for anti-PD-1 monotherapy outcome in metastatic non-small cell lung cancer (NSCLC). METHODS: The GuardantOMNI pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jii Bum, Park, Hyung Soon, Choi, Su Jin, Heo, Seong Gu, An, Ho Jung, Kim, Hye Ryun, Hong, Min Hee, Lim, Sun Min, Chang, Kyle, Quinn, Katie, Odegaard, Justin, Shim, Byoung Yong, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Genomic Biomarkers in Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761799/
https://www.ncbi.nlm.nih.gov/pubmed/36544541
http://dx.doi.org/10.1177/17588359221141761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761799/
https://www.ncbi.nlm.nih.gov/pubmed/36544541
http://dx.doi.org/10.1177/17588359221141761

Ejemplares similares